Premium
O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520
Author(s) -
Ufer Mike,
Rouzade-Dominguez Marie-Laure,
Huledal Gunilla,
Pezous Nicole,
Avrameas Alexandre,
David Olivier,
Kretz Sandrine,
Kucher Klaus,
Neumann Ulf,
Cha Jang-Ho,
Graf Ana,
Lopez-Lopez Cristina
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.351
Subject(s) - tolerability , medicine , placebo , pharmacodynamics , pharmacokinetics , dosing , adverse effect , asymptomatic , pharmacology , vital signs , anesthesia , gastroenterology , pathology , alternative medicine
Luc Tritsmans, Luc Van Nueten, Niels Andreassen, Sebastiaan Engelborghs, Janssen Research & Development, Beerse, Belgium; 2 Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M€ olndal, Sweden; Ortho-McNeil Pharmaceutical, Raritan, NJ, USA; Janssen Research & Development, Titusville, NJ, USA; 5 Hospital Mutua de Terrasa, Servicio de Neurologia, Terrassa, Spain; Hospital Universitario La Paz, Madrid, Spain; Hospital Clinico San Carlos, Servicio de Neurologia, Madrid, Spain; Fundaci o ACE, Barcelona, Alzheimer Treatment & Research Center, Barcelona, Spain; 9 Hospital Universitari La Fe Avinguda Abril Martorell, Valencia, Spain; Karolinska Institutet, Stockholm, Sweden; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium. Contact e-mail: jstreffe@its.jnj.com